Castle Biosciences Quarterly Cash Flow Statement
NASDAQ: CSTLHealth CareMedical SpecialitiesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Castle Biosciences free cash flow
In the quarter ended Jun 30, 2026, Castle Biosciences generated $15.2 million of operating cash flow and spent $8.7 million on capital expenditures. That left free cash flow of $6.6 million, a free-cash-flow margin of 6.3% of revenue. Free cash flow was down 43.3% from the prior year's $11.6 million.
Summary generated from market data by MetaCap's automated system. Methodology
Castle Biosciences cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -2.06M | -14.52M | -2.33M | -501.00K | 4.52M | -25.85M | 9.59M | 2.27M | 8.92M | -2.53M | -2.58M | -6.91M |
| Net Income growth (YoY) | -145.54% | — | -124.32% | -122.08% | -49.29% | — | — | — | — | — | — | — |
| Depreciation & Amortization | 4.07M | 3.93M | 3.78M | 3.82M | 3.41M | 29.76M | 5.77M | 3.54M | 3.35M | 3.34M | 3.22M | 3.17M |
| Stock-Based Compensation | 11.59M | 9.78M | 11.41M | 12.10M | 11.21M | 11.18M | 11.44M | 13.03M | 13.18M | 12.68M | 11.80M | 13.04M |
| Change in Working Capital | -8.50M | 3.53M | 4.34M | 2.97M | 3.49M | -3.35M | -2.60M | -5.14M | -4.58M | -4.62M | -185.00K | -6.20M |
| Operating Cash Flow | 15.20M | -22.13M | 26.93M | 22.63M | 20.82M | -6.04M | 24.36M | 23.34M | 24.00M | -6.83M | 18.59M | 5.01M |
| Capital Expenditures | -8.65M | -12.46M | -7.18M | -14.83M | -9.26M | -4.74M | -7.57M | -6.38M | -5.23M | -9.15M | -3.79M | -2.46M |
| Investing Cash Flow | -15.96M | -25.80M | 8.83M | -18.39M | -28.38M | -22.43M | 5.77M | -14.79M | -21.42M | -19.70M | -7.67M | -9.71M |
| Debt Issued | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10.00M | 0 | 0 |
| Financing Cash Flow | -886.00K | -5.03M | -4.59M | -919.00K | 101.00K | -1.55M | -5.38M | 838.00K | 42.00K | 10.64M | -3.30M | 45.00K |
| Net Change in Cash | -1.65M | -52.97M | 31.17M | 3.32M | -7.46M | -30.02M | 24.75M | 9.39M | 2.62M | -15.89M | 7.62M | -4.65M |
| Free Cash Flow | 6.55M | -34.58M | 19.75M | 7.80M | 11.56M | -10.78M | 16.80M | 16.96M | 18.77M | -15.99M | 14.79M | 2.56M |
This table shows 12 quarterly periods of Castle Biosciences's cash flow statement, from Q2 2026 back to Q3 2023, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow CSTL's reporting calendar. What is a cash flow statement?